Soleno Therapeutics SLNO Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Refocuses on Clinical Milestones RNR Q1 2026 Earnings Strong Underwriting and Investment Results Drive EPS Beat LNKB Q4 2025 Earnings EPS Misses Estimates by Wide Margin Stock Unchanged CVCO Q1 2026 Earnings EPS Slightly Exceeds Estimates Stock Gains 36 FOR Q1 2026 Earnings EPS Misses Estimates by a Narrow Margin Stock Gains 36 BN Q1 2026 Earnings EPS Surpasses Estimates Amid Slight Stock Decline